Evoke Pharma, Inc. (EVOK)
- Previous Close
0.5500 - Open
0.6000 - Bid 0.3990 x 200
- Ask 0.7280 x 200
- Day's Range
0.5599 - 0.6000 - 52 Week Range
0.4000 - 1.9600 - Volume
64,971 - Avg. Volume
33,826 - Market Cap (intraday)
4.815M - Beta (5Y Monthly) 0.35
- PE Ratio (TTM)
-- - EPS (TTM)
-1.8300 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
www.evokepharma.com4
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: EVOK
Performance Overview: EVOK
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EVOK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EVOK
Valuation Measures
Market Cap
4.81M
Enterprise Value
111.79k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.44
Price/Book (mrq)
1.38
Enterprise Value/Revenue
0.02
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-116.76%
Return on Assets (ttm)
-37.66%
Return on Equity (ttm)
-253.55%
Revenue (ttm)
6.11M
Net Income Avi to Common (ttm)
-7.13M
Diluted EPS (ttm)
-1.8300
Balance Sheet and Cash Flow
Total Cash (mrq)
9.7M
Total Debt/Equity (mrq)
142.97%
Levered Free Cash Flow (ttm)
-3.83M